Reference-based pricing schemes: effect on pharmaceutical expenditure, resource utilisation and health outcomes
LL Ioannides-Demos, JE Ibrahim, JJ McNeil - Pharmacoeconomics, 2002 - Springer
Pharmaceutical expenditure is rising more rapidly than the general inflation rate in most
advanced countries. One strategy that has been introduced to control pharmaceutical costs …
advanced countries. One strategy that has been introduced to control pharmaceutical costs …
Pharmaceutical policies in Canada: another example of federal-provincial discord
AH Anis - CMAJ, 2000 - Can Med Assoc
Pharmaceutical policy in Canada is set at both the federal and provincial levels of
government. The federal government is responsible for intellectual property rights of …
government. The federal government is responsible for intellectual property rights of …
[HTML][HTML] Outcomes of reference pricing for angiotensin-converting–enzyme inhibitors
Background In January 1997, reference pricing for angiotensin-converting–enzyme (ACE)
inhibitors for patients 65 years of age or older was introduced in British Columbia, Canada …
inhibitors for patients 65 years of age or older was introduced in British Columbia, Canada …
Clinical and economic consequences of a reimbursement restriction of nebulised respiratory therapy in adults: direct comparison of randomised and observational …
Objective To compare the results of a randomised and an observational evaluation of the
same policy that restricted reimbursement for nebulised respiratory medications in adult …
same policy that restricted reimbursement for nebulised respiratory medications in adult …
Health services databases in Saskatchewan
W Downey, M Stang, P Beck, W Osei… - …, 2006 - Wiley Online Library
Saskatchewan is one of ten provinces and three territories in Canada. It is located in western
Canada and has a relatively stable population of about one million people, or about 3.2% of …
Canada and has a relatively stable population of about one million people, or about 3.2% of …
Impact of reference-based pricing of nitrates on the use and costs of anti-anginal drugs
PV Grootendorst, LR Dolovich, BJ O'Brien… - Cmaj, 2001 - Can Med Assoc
Background: Reference-based pricing limits reimbursement for a group of drugs that are
deemed therapeutically equivalent to the cost of the lowest-priced product within that group …
deemed therapeutically equivalent to the cost of the lowest-priced product within that group …
Pharmaceutical cost control in Canada: does it work?
D Menon - Health Affairs, 2001 - healthaffairs.org
Governments in Canada have instituted mechanisms intended to control drug prices. These
include the establishment of a semi-judicial body by the federal government to control …
include the establishment of a semi-judicial body by the federal government to control …
Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers
S Schneeweiss, SB Soumerai… - Clinical …, 2003 - Wiley Online Library
Objective Reference pricing is a medication cost‐sharing policy that fully covers medications
which are less expensive than a standard reference price and requires patients to pay the …
which are less expensive than a standard reference price and requires patients to pay the …
Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization
Background: Increasing copayments for higher-priced prescription medications has been
suggested as a means to help finance drug coverage for elderly patients, but evaluations of …
suggested as a means to help finance drug coverage for elderly patients, but evaluations of …
What is required to evaluate the impact of pharmaceutical reference pricing?
J Puig-Junoy - Applied Health Economics and Health Policy, 2005 - Springer
Objective To describe empirical studies evaluating the impact of reference pricing (RP)
interventions in pharmaceutical markets in order to discuss the requirements for these …
interventions in pharmaceutical markets in order to discuss the requirements for these …